A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

The constant threat of recurrence feels like the proverbial sword of Damocles — always present, always waiting. If my cancer does return, the now-inert metal seeds scattered through my prostate and ...

Androgen Deprivation Therapy (ADT) ADT, says Dr. Armstrong, was the subject of the very first Nobel Prize in Medicine related to cancer, won by Charles B. Huggins in 1966.

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...

Androgen Deprivation Therapy (ADT) ADT, says Dr. Armstrong, was the subject of the very first Nobel Prize in Medicine related to cancer, won by Charles B. Huggins in 1966. [ 2 ] ...

Among patients with metastatic hormone-sensitive prostate cancer, the treatment combination of Nubeqa (darolutamide) and androgen deprivation therapy (ADT) has reportedly displayed positive results ...

In this article, Sandy Srinivas, MD, discusses androgen deprivation therapy as a treatment for advanced prostate cancer and examines potential avenues for future research, including androgen ...

The utilization of Xtandi (enzalutamide), compared with Zytiga (abiraterone) — both in combination with androgen deprivation therapy — in the treatment of patients with prostate cancer may be ...

The need to balance the oncological benefits of androgen deprivation therapy (ADT) with patient quality of life (QOL) outcomes has investigators from around the world calling for both careful ...

Androgen-deprivation therapy (ADT) is well established as the standard of care in metastatic prostate cancer (PCa) management; however, ADT has significant adverse effects (AEs) that must be ...

Recently, combined therapy with androgen deprivation therapy and androgen receptor pathway inhibitors has been recommended for metastatic hormone-sensitive prostate cancer patients.

A recent cohort study evaluated the risk of developing Alzheimer dementia after ADT in 16,888 men with prostate cancer, 14.2% of whom were treated with ADT. Androgen deprivation therapy (ADT) is ...